Also, no association between survival and TERT promotor mutation status was found in the subgroups of patients with MGMT promotor methylation (HR for IDHwt/TERTwt: 0.99, CI: 0.6–1.8), unmethylated MGMT promotor status (HR for IDHwt/TERTwt: 0.92, CI: 0.5–1.7), first-line radiochemotherapy per EORTC 26981/22981 (HR for IDHwt/TERTwt: 1.00, CI: 0.7–1.4), or classical histopathological findings of glioblastoma (HR for IDHwt/TERTwt: 1.06, CI: 0.8–1.5). This evidence concerns the gene MGMT and glioblastoma.